Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1986-9-17
|
| pubmed:abstractText |
The electrophysiologic effects of a new antiarrhythmic agent, cibenzoline, were investigated in 25 patients with an average age of 62 years. The compound was administered intravenously, as a bolus given over 2 minutes, then as a slow infusion over 40 minutes. Each subject was randomly allocated to receive one of the following four doses: 1.55 mg/kg (six patients), 1.8 mg/kg (six patients), 2.2 mg/kg (six patients), or 2.6 mg/kg (seven patients). Plasma cibenzoline concentrations at these doses were 378 +/- 80,525 +/- 194, 618 +/- 72, and 731 +/- 196 ng/ml, respectively. Administration of 1.55 mg/kg cibenzoline significantly shortened the sinus cycle (60 msec on average; p less than 0.025) and increased intraatrial (+8 msec; p less than 0.05) and His-Purkinje conduction times (HV interval + 13 msec; p less than 0.001). At 1.80 mg/kg, prolongation occurred in the HV interval (+9 msec; p less than 0.02), the duration of the QRS complex (+20 msec; p greater than 0.05), and the QT interval (+18 msec; p less than 0.025). At the higher doses these changes became more marked (maximum increase: HV = +16 msec, p less than 0.001; QRS + 25 msec; p less than 0.001; QT + 26 msec, p less than 0.05), and additional effects on atrioventricular nodal conduction time (AH interval + 17 msec; p less than 0.05) and atrial (+20 msec; p less than 0.05) and ventricular (+10 msec; p greater than 0.05) effective refractory periods were observed. Prolongation of the QRS duration was the effect that correlated best with plasma cibenzoline levels (r = 0.47; p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0002-8703
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
112
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
333-9
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:3526853-Adult,
pubmed-meshheading:3526853-Aged,
pubmed-meshheading:3526853-Anti-Arrhythmia Agents,
pubmed-meshheading:3526853-Atrioventricular Node,
pubmed-meshheading:3526853-Cardiac Pacing, Artificial,
pubmed-meshheading:3526853-Clinical Trials as Topic,
pubmed-meshheading:3526853-Electrocardiography,
pubmed-meshheading:3526853-Electrophysiology,
pubmed-meshheading:3526853-Female,
pubmed-meshheading:3526853-Heart Conduction System,
pubmed-meshheading:3526853-Humans,
pubmed-meshheading:3526853-Imidazoles,
pubmed-meshheading:3526853-Male,
pubmed-meshheading:3526853-Middle Aged,
pubmed-meshheading:3526853-Myocardial Contraction,
pubmed-meshheading:3526853-Random Allocation,
pubmed-meshheading:3526853-Sinoatrial Node,
pubmed-meshheading:3526853-Time Factors
|
| pubmed:year |
1986
|
| pubmed:articleTitle |
Electrophysiologic effects of cibenzoline in humans related to dose and plasma concentration.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|